Literature DB >> 25662856

A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.

Rolando Pajon1, Carolyn M Buckwalter2, Kay O Johswich2, Scott D Gray-Owen2, Dan M Granoff1.   

Abstract

BACKGROUND: The effect of protein-based meningococcal vaccines on prevention of nasopharyngeal colonization has been difficult to investigate experimentally because a reliable animal colonization model did not exist.
METHODS: Human CEACAM1 transgenic mice, which can be colonized by meningococci, were immunized IP with one of two meningococcal native outer membrane vesicle (NOMV) vaccines prepared from mutants with attenuated endotoxin (lpxL1 knockout) and over-expressed sub-family B Factor H-binding proteins (FHbp). Animals were challenged intranasally two weeks after the third dose with wild-type strain H44/76, or were treated IP with anti-NOMV serum before and during the bacterial challenge.
RESULTS: The NOMV-1 vaccine, prepared from the serogroup B H44/76 mutant, elicited ∼40-fold higher serum bactericidal antibody titers against the wild-type H44/76 challenge strain than the NOMV-2 vaccine prepared from a heterologous serogroup W mutant strain with different PorA and FHbp amino acid sequence variants. Compared to aluminum hydroxide-immunized control mice, the efficacy for prevention of any H44/76 colonization was 93% (95% confidence interval, 52-99, P<0.0001) for the NOMV-1 vaccine, and 19% (-3-36, P=0.23) for NOMV-2. NOMV-2-vaccinated mice had a 5.6-fold decrease in geometric mean CFU of bacteria per animal in tracheal washes compared to control mice (P=0.007). The efficacy of passive administration of serum from NOMV-1-vaccinated mice to immunologically naïve mice against colonization was 44% (17-61; P=0.002).
CONCLUSIONS: Both NOMV vaccines protected against meningococcal colonization but there was greater protection by the NOMV-1 vaccine with antigens matched with the challenge strain. Meningococcal vaccines that target protein antigens have potential to decrease colonization.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Colonization model; FHbp; Factor H binding protein; Neisseria meningitidis; OMV; PorA; Vaccine

Mesh:

Substances:

Year:  2015        PMID: 25662856      PMCID: PMC4361389          DOI: 10.1016/j.vaccine.2015.01.057

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  49 in total

1.  A universal vaccine for serogroup B meningococcus.

Authors:  Marzia M Giuliani; Jeannette Adu-Bobie; Maurizio Comanducci; Beatrice Aricò; Silvana Savino; Laura Santini; Brunella Brunelli; Stefania Bambini; Alessia Biolchi; Barbara Capecchi; Elena Cartocci; Laura Ciucchi; Federica Di Marcello; Francesca Ferlicca; Barbara Galli; Enrico Luzzi; Vega Masignani; Davide Serruto; Daniele Veggi; Mario Contorni; Maurizio Morandi; Alessandro Bartalesi; Vanda Cinotti; Donatella Mannucci; Francesca Titta; Elisa Ovidi; Jo Anne Welsch; Dan Granoff; Rino Rappuoli; Mariagrazia Pizza
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-06       Impact factor: 11.205

2.  Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.

Authors:  Paul A Kristiansen; Fabien Diomandé; Absatou Ky Ba; Idrissa Sanou; Abdoul-Salam Ouédraogo; Rasmata Ouédraogo; Lassana Sangaré; Denis Kandolo; Flavien Aké; Inger Marie Saga; Thomas A Clark; Lara Misegades; Stacey W Martin; Jennifer Dolan Thomas; Sylvestre R Tiendrebeogo; Musa Hassan-King; Mamoudou H Djingarey; Nancy E Messonnier; Marie-Pierre Préziosi; F Marc Laforce; Dominique A Caugant
Journal:  Clin Infect Dis       Date:  2012-10-19       Impact factor: 9.079

3.  Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys.

Authors:  Oliver Koeberling; Anja Seubert; George Santos; Annalisa Colaprico; Mildred Ugozzoli; John Donnelly; Dan M Granoff
Journal:  Vaccine       Date:  2011-05-13       Impact factor: 3.641

4.  Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.

Authors:  Giacomo Frosi; Alessia Biolchi; Morena Lo Sapio; Fabio Rigat; Stefanie Gilchrist; Jay Lucidarme; Jamie Findlow; Ray Borrow; Mariagrazia Pizza; Marzia Monica Giuliani; Duccio Medini
Journal:  Vaccine       Date:  2013-08-14       Impact factor: 3.641

5.  A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination.

Authors:  Peter T Beernink; Jutamas Shaughnessy; Emily M Braga; Qin Liu; Peter A Rice; Sanjay Ram; Dan M Granoff
Journal:  J Immunol       Date:  2011-02-16       Impact factor: 5.422

6.  Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.

Authors:  Jamie Findlow; Ray Borrow; Matthew D Snape; Tom Dawson; Ann Holland; Tessa M John; Anita Evans; Karen L Telford; Ellen Ypma; Daniela Toneatto; Philipp Oster; Elizabeth Miller; Andrew J Pollard
Journal:  Clin Infect Dis       Date:  2010-10-18       Impact factor: 9.079

7.  Generation of human CEACAM1 transgenic mice and binding of Neisseria Opa protein to their neutrophils.

Authors:  Angel Gu; Zhifang Zhang; Nan Zhang; Walter Tsark; John E Shively
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

8.  Vaccine potential of the Neisseria meningitidis 2086 lipoprotein.

Authors:  Leah D Fletcher; Liesel Bernfield; Vicki Barniak; John E Farley; Alan Howell; Melissa Knauf; Peggy Ooi; Robert P Smith; Paige Weise; Mike Wetherell; Xiaoling Xie; Robert Zagursky; Ying Zhang; Gary W Zlotnick
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

9.  Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-β-dependent mechanisms.

Authors:  Y Liu; E A Islam; G A Jarvis; S D Gray-Owen; M W Russell
Journal:  Mucosal Immunol       Date:  2012-02-22       Impact factor: 7.313

10.  Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].

Authors:  D M Daugla; J P Gami; K Gamougam; N Naibei; L Mbainadji; M Narbé; J Toralta; B Kodbesse; C Ngadoua; M E Coldiron; F Fermon; A-L Page; M H Djingarey; S Hugonnet; O B Harrison; L S Rebbetts; Y Tekletsion; E R Watkins; D Hill; D A Caugant; D Chandramohan; M Hassan-King; O Manigart; M Nascimento; A Woukeu; C Trotter; J M Stuart; McJ Maiden; B M Greenwood
Journal:  Lancet       Date:  2013-09-12       Impact factor: 79.321

View more
  8 in total

1.  Discordant Effects of Licensed Meningococcal Serogroup B Vaccination on Invasive Disease and Nasal Colonization in a Humanized Mouse Model.

Authors:  Carolyn M Buckwalter; Elissa G Currie; Raymond S W Tsang; Scott D Gray-Owen
Journal:  J Infect Dis       Date:  2017-05-15       Impact factor: 5.226

2.  A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine.

Authors:  Rolando Pajon; Eduardo Lujan; Dan M Granoff
Journal:  Vaccine       Date:  2015-12-20       Impact factor: 3.641

Review 3.  Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants.

Authors:  Roger Baxter; Pavitra Keshavan; Jo Anne Welsch; Linda Han; Igor Smolenov
Journal:  Hum Vaccin Immunother       Date:  2016-02-01       Impact factor: 3.452

4.  Contribution of factor H-Binding protein sequence to the cross-reactivity of meningococcal native outer membrane vesicle vaccines with over-expressed fHbp variant group 1.

Authors:  Arianna Marini; Omar Rossi; Maria Grazia Aruta; Francesca Micoli; Simona Rondini; Serafina Guadagnuolo; Isabel Delany; Ian R Henderson; Adam F Cunningham; Allan Saul; Calman A MacLennan; Oliver Koeberling
Journal:  PLoS One       Date:  2017-07-25       Impact factor: 3.240

5.  Biological feasibility and importance of a gonorrhea vaccine for global public health.

Authors:  Leah R Vincent; Ann E Jerse
Journal:  Vaccine       Date:  2018-04-18       Impact factor: 3.641

6.  The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae.

Authors:  Isabelle Leduc; Kristie L Connolly; Afrin Begum; Knashka Underwood; Stephen Darnell; William M Shafer; Jacqueline T Balthazar; Andrew N Macintyre; Gregory D Sempowski; Joseph A Duncan; Marguerite B Little; Nazia Rahman; Eric C Garges; Ann E Jerse
Journal:  PLoS Pathog       Date:  2020-12-08       Impact factor: 6.823

7.  Chimeric hepatitis B virus core particles displaying Neisserial surface protein A confer protection against virulent Neisseria meningitidis serogroup B in BALB/c mice.

Authors:  YongLi Hou; Ting Yan; Hui Cao; Peng Liu; Kang Zheng; Zhenyu Li; Qing Deng; SiHai Hu
Journal:  Int J Nanomedicine       Date:  2019-08-16

Review 8.  Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions.

Authors:  Eric Y Lin; Paul C Adamson; Jeffrey D Klausner
Journal:  Drugs       Date:  2021-06-07       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.